alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1261 Copper sulfate. ( a ) Copper sulfate (cupric sulfate, CuSO4·5 H2O, CAS Reg. No. 7758-99-8) usually is used in the pentahydrate form. This form occurs as large, deep blue or ultramarine, triclinic crystals; as blue granules, or as a light blue powder. The ingredient is prepared by the reaction of sulfuric acid with cupric oxide or with copper metal.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a nutrient supplement as defined in § 170.3(o)(20) of this chapter and as a processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice. Copper sulfate may be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the Act) or with regulations promulgated under section 412(a)(2) of the Act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[49 FR 24119, June 12, 1984, as amended at 73 FR 8607, Feb. 14, 2008; 76 FR 59249, Sept. 26, 2011]
§ 20.82 Discretionary disclosure by the Commissioner. ( a ) Except as provided in paragraph (b) of this section, the Commissioner may, in his or her discretion, disclose part or all of any Food and Drug Administration (FDA) record that is otherwise exempt from disclosure pursuant to subpart D of this part. As set forth in § 20.20(b), FDA will withhold requested information only if: ( 1 ) The Agency reasonably foresees that disclosure would harm an interest protected by an exemption described in this part; or
( 2 ) Disclosure is prohibited by law. FDA shall exercise its discretion to disclose such records whenever it determines that such disclosure is in the public interest, will promote the objectives of the Freedom of Information Act and the Agency, and is, for example, consistent with the rights of individuals to privacy, the property rights of persons in trade secrets, and the need for the Agency to promote frank internal policy deliberations and to pursue its regulatory activities without disruption.
( b ) The Commissioner shall not make available for public disclosure any record that is: ( 1 ) Exempt from public disclosure pursuant to § 20.61.
( 2 ) Exempt from public disclosure pursuant to § 20.63.
( 3 ) Prohibited from public disclosure under statute.
( 4 ) Contained in a Privacy Act Record System where disclosure would constitute a clearly unwarranted invasion of personal privacy or is otherwise in violation of 5 U.S.C. 552a(b), as applied in part 21, subpart G, of this chapter (restrictions on disclosure in the privacy regulations).
( c ) Discretionary disclosure of a record pursuant to this section shall invoke the requirement that the record shall be disclosed to any person who requests it pursuant to § 20.21, but shall not set a precedent for discretionary disclosure of any similar or related record and shall not obligate the Commissioner to exercise his discretion to disclose any other record that is exempt from disclosure.
[42 FR 15616, Mar. 22, 1977, as amended at 70 FR 41958, July 21, 2005; 87 FR 55913, Sept. 13, 2022]
Exhibit 3.2.2

SECOND AMENDMENT TO  BYLAWS OF BALLANTYNE OF OMAHA, INC.,  A Delaware corporation

The Bylaws of Ballantyne of Omaha, Inc., a Delaware corporation, are hereby amended as follows:

1.     Article 2,
Board of Directors. The following Section 4 is hereby amended to read as follows:



|    |  | BALLANTYNE OF OMAHA, INC.                   
|--- |  | --------------------------------------------
|By: |  | /s/JOHN P. WILMERSJohn P. Wilmers, President

Attest:

|/s/BRAD FRENCHBrad French, Secretary |  | 
|------------------------------------ |  | 

---



QuickLinks
[Federal Register Volume 75, Number 39 (Monday, March 1, 2010)]
[Notices]
[Page 9202]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4091]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EF10-5-000]


Western Area Power Administration; Notice of Filing

February 19, 2010.
    Take notice that on February 2, 2010, the Deputy Secretary of the 
Department of Energy, under the authority vested in the Federal Energy 
Regulatory Commission by Delegation Order No. 00-037.00, submitted Rate 
Order No. WAPA-149, the power rate formula for the Provo River Project, 
for confirmation and final approval to be effective April 1, 2010, and 
ending March 31, 2015.
    Any person desiring to intervene or to protest this filing must 
file in accordance with Rules 211 and 214 of the Commission's Rules of 
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be 
considered by the Commission in determining the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceeding. Any person wishing to become a party must file a notice of 
intervention or motion to intervene, as appropriate. Such notices, 
motions, or protests must be filed on or before the comment date. On or 
before the comment date, it is not necessary to serve motions to 
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an 
original and 14 copies of the protest or intervention to the Federal 
Energy Regulatory Commission, 888 First Street, NE., Washington, DC 
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the 
``eLibrary'' link and is available for review in the Commission's 
Public Reference Room in Washington, DC. There is an ``eSubscription'' 
link on the Web site that enables subscribers to receive e-mail 
notification when a document is added to a subscribed docket(s). For 
assistance with any FERC Online service, please e-mail 
<a href="/cdn-cgi/l/email-protection#4a0c0f180905242623242f193f3a3a25383e0a2c2f3829642d253c"><span class="__cf_email__" data-cfemail="72343720313d1c1e1b1c17210702021d000632141700115c151d04">[email protected]</span></a>, or call (866) 208-3676 (toll free). For 
TTY, call (202) 502-8659.
    Comment Date: 5 p.m. Eastern Time on March 4, 2010.

Kimberly D. Bose,
Secretary.
[FR Doc. 2010-4091 Filed 2-26-10; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

DONALD ANTHONY BURKHART JR.,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 64 MM 2022

ORDER

PER CURIAM

AND NOW , this 17 th day of October , 2022, the “Petition/Motion Seeking Court

Appointed Said Counsel” and the “Application for Leave to File, Oversized

Brief/Application for Allowance of Appeal, to Exceed Word/Page Count Limits” are

DENIED. Petitioner is allotted 15 days in which to file a compliant Petition for Allowance

of Appeal.
§ 520.2042 Pyrantel pamoate tablets. ( a ) *Specifications.* Each tablet contains pyrantel pamoate equivalent to 22.7, 45.4, or 113.5 milligrams of pyrantel base.
( b ) *Sponsor.* See No. 017135 in § 510.600(c) of this chapter.
( c ) *Conditions of use.* It is used for dogs as follows: ( 1 ) *Amount.* For dogs weighing over 5 pounds, use at least 2.27 milligrams of pyrantel base per pound of body weight; for dogs weighing 5 pounds or less, use at least 4.54 milligrams of pyrantel base per pound of body weight.
( 2 ) *Indications for use.* For removal and control of large roundworms (ascarids) (*Toxocara canis* and *Toxascaris leonina*), and hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*).
( 3 ) *Limitations.* Administer orally directly or in a small amount of food. To prevent reinfection of *T. canis* in puppies, lactating bitches after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 weeks of age; treat lactating bitches 2 to 3 weeks after whelping; routinely treat adult dogs monthly. Do not withhold food prior to or after treatment. The presence of these parasites should be confirmed by laboratory fecal examination. A followup fecal examination should be conducted 2 to 4 weeks after first treatment regimen to determine the need for re-treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[43 FR 52700, Nov. 14, 1978, as amended at 49 FR 22073, May 25, 1984; 57 FR 48163, Oct. 22, 1992; 58 FR 44611, Aug. 24, 1993]
# EPA- SwRI Update ( 11 - 15 - 15) • Testing Plan for Alternative Approach at SwRI – Cummins ISB 300hp rating (24 points) - completed 

### – Cummins ISB 200hp rating (24 points) – Navistar N13 455hp rating (27 points) - completed – N13 engine with 365hp rating (27 points) - n ot started yet – Ford 6.8 liter gasoline engine - not started yet 1 DRAFT & DELIBERATIVE

# Mapping Points for ARB Cycle for ISB

DRAFT & DELIBERATIVE 2 • Use 300hp rating map to predict 200hp rating • Green Points – 300hp rating • Red points – 200hp rating

# Numerical Approaches • Triangulation (EPA’s interpolation/extrapolation) • Model 1 – Global regression as function of N/V and N/V*W • Model 3a – Global linear regression as function of N/V and W • Model 3b – Global regression as function of N/V and W – Regression model based on "hundreds" of GEM results • Note: – We totally abandoned strong nonlinear global regression as function of N/V, N/V^2 and N/V*W DRAFT & DELIBERATIVE 3

# Results with four methods (ARB)

DRAFT & DELIBERATIVE 4

# Next Steps • N13 engine Child rating evaluation with 365hp rating 

### (27 points) • Finalize numerical schemes DRAFT & DELIBERATIVE 5
Exhibit 32.2


               CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
                            AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


 In connection with the Quarterly Report of First Health Group Corp. (the
 "Company") on Form 10-Q for the period ended September 30, 2004, as filed
 with the Securities and Exchange Commission on the date hereof (the
 "Report"), I, William R. McManaman, Chief Financial Officer of the Company,
 do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
 to Section 906 of the Sarbanes-Oxley Act of 2002, that:

      (1)  The Report fully complies with the requirements of Section 13(a)
 or 15(d) of the Securities Exchange Act of 1934; and

      (2)  The information contained in the Report fairly presents, in all
 material respects, the financial condition and results of operations of the
 Company.


 /s/ William R. McManaman

 William R. McManaman
 Senior Vice President and Chief Financial Officer
 November 5, 2004
§ 335.3 Definitions. As used in this part: ( a ) *Antidiarrheal.* A drug that can be shown by objective measurement to treat or control (stop) the symptoms of diarrhea.
( b ) *Diarrhea.* A condition characterized by increased frequency of loose, watery stools (three or more daily) during a limited period (24 to 48 hours), usually with no identifiable cause.
( c ) *Travelers' diarrhea.* A subset of diarrhea occurring in travelers that is most commonly caused by an infectious agent.
[68 FR 18881, Apr. 17, 2003, as amended at 69 FR 26302, May 12, 2004]
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3900 Sodium pentachlorophenate.

Sodium pentachlorophenate may be safely used as a preservative for ammonium alginate employed as a processing aid in the manufacture of polyvinyl chloride emulsion polymers intended for use as articles or components of articles that contact food at temperatures not to exceed room temperature. The quantity of sodium pentachlorophenate used shall not exceed 0.5 percent by weight of ammonium alginate solids.
<PAGE>   1
                                                                    Exhibit 23.2


             REPORT ON SCHEDULE AND CONSENT OF INDEPENDENT AUDITOR

The Board of Directors
Innova Corporation

The audits referred to in our report dated April 30, 1997, except as to Note
17, which is as of June 17, 1997, included the related financial statement
schedule as of December 31, 1996, and for each of years in the two-year period
ended March 31, 1996 and or the nine months ended December 31, 1996, included
in the registration statement.  This financial statement schedule is the
responsibility of the Company's management.  Our responsibility is to express an
opinion on the financial statement schedule based on our audits.  In our
opinion, such financial statement schedule, when considered in relation to the
basic consolidated financial statements taken as a whole, present fairly in all
material respects the information set forth therein.

We consent to the use of our reports included herein and to the reference to
our firm under the headings "Experts" and "Selected Financial Data" in the
prospectus.


/s/ KPMG Peat Marwick LLP
-------------------------

Seattle, Washington
July 23, 1997
§ 520.905d Fenbendazole powder. ( a ) *Specifications.* Each 2-ounce packet contains 2.27 grams (4 percent) fenbendazole.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.275 of this chapter.
( d ) *Conditions of use.* It is administered to swine as follows: ( 1 ) *Amount.* 3 milligrams fenbendazole per kilogram body weight per day (1.36 milligrams per pound per day).
( 2 ) *Indications for use.* For removal and control of large roundworms (*Ascaris suum*); lungworms (*Metastrongylus apri*); nodular worms (*Oesophagostomum dentatum, O. quadrispinulatum*); small stomach worms (*Hyostrongylus rubidus*); whipworms (*Trichuris suis*); and kidneyworms (*Stephanurus dentatus*— mature and immature).
( 3 ) *Limitations.* Thoroughly mix the contents of the packet(s) with swine ration and administer according to label directions. Feed as sole ration for 3 consecutive days. Can be fed to pregnant sows. No prior withdrawal of feed or water is necessary. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[49 FR 18090, Apr. 27, 1984, as amended at 49 FR 20485, May 15, 1984; 66 FR 47960, Sept. 17, 2001; 70 FR 32489, June 3, 2005; 74 FR 61516, Nov. 25, 2009; 83 FR 48945, Oct. 9, 2018]
# AP P E N D IX D : CONCEPTUAL WRAP AND SELECTED EDMS COMPARISONConceptual WRAP and Selected Existing EDMS ComparisonConceptualWRAP EDMSNationalEmissionsInventoryTribal EmissionsInventorySoftwareSolutionCalifornia AirResources BoardEmissionsInventoryColoradoDepartment ofHealth AirPollution InventoryDelawareEnvironmentalNavigatorData Tracking1Pollutants 9 7 7 5 5 5Sources 6 4 3 3 3 3Activity Data Yes Yes Yes Yes Yes YesEmissions Factors Yes Yes Yes No No NoTemporal Resolution Variable2Annual Annual Annual Annual AnnualSpatial ResolutionCounty /Reservation / PointCounty / PointReservation /PointCounty / Point County / Point County / PointStandard Submission Format Yes Yes No3Yes No4NoData QA/QC1Submission Format Check Yes Yes No3Yes No4NoContent Validation Yes Yes Yes Yes No4YesSubmission Completeness Yes Yes Yes Yes No4NoData Reporting1Standard Summary Reports Yes Yes Yes Yes YesYesRegional Haze Rule Specific ReportsYes No No No No NoData Exports Yes Yes Yes Minimal MinimalYesModel Ready Input File, i.e. SMOKE Yes No No No NoNoGIS Component1Multiple Display Tools Provided Yes No Yes No Yes YesAbility to Query Emissions Database andDisplay ResultsYes No Yes No Yes YesUser Access and Preferences1Publicly Accessible via Internet Yes Yes No Yes Yes Yes1See Sections 3.1 and 3.3 for the description of the conceptual WRAP EDMS and the selected existing EDMS2Some emissions data will be submitted at the hourly, daily, seasonal, or annual levels. However, the reporting temporal resolution will be annual.3TEISS does not have one standard submission format. In fact TEISS accepts many formats.4This system is not the primary emission inventory system for Colorado. It is a secondary system included in this analysis because of its GIS capability.
Exhibit 24  POWER OF ATTORNEY  The director of Ballantyne Strong, Inc. (the Company), whose signature appears below, hereby appoints Gary L. Cavey and Kevin S. Herrmann, or either of them, as his attorney to sign, in his name and behalf and in any and all capacities stated below, the Companys Annual Report on Form 10-K pursuant to Section 13 of the Securities Exchange Act of 1934, and likewise to sign any and all amendments and other documents relating thereto as shall be necessary, such person hereby granting to each such attorney power to act with or without the other and full power of substitution and revocation, and hereby ratifying all that any such attorney or his substitute may do by virtue hereof.  This Power of Attorney has been signed by the following persons in the capacity indicated.   /s/   William F. Welsh IIWilliam   F. Welsh, II, ChairmanDate:   March 12, 2011/s/   Alvin AbramsonAlvin   Abramson, DirectorDate:   March 11, 2011/s/   Christopher E. BeachChristopher   E. Beach, DirectorDate:   March 14, 2011/s/   Marc E. LeBaronMarc   E. LeBaron, DirectorDate:   March 15, 2011/s/   Mark D. HasebroockMark   D. Hasebroock, DirectorDate:   March 11, 2011
#### § 20.42 Aggregation of certain requests.

The Food and Drug Administration may aggregate certain requests by the same requester, or by a group of requesters acting in concert, if the requests involve clearly related matters and the agency reasonably believes that such requests actually constitute a single request which would otherwise satisfy the unusual circumstances specified in § 20.41(b)(3)(ii)(B). FDA may extend the time for processing aggregated requests in accordance with the unusual circumstances provisions of § 20.41.

[68 FR 25286, May 12, 2003]
Exhibit 31.1

 

**CERTIFICATION**

 

I, Terrence J. Scully,certify that:

 

1.  I have reviewed this annual report on Form10-K/A, and all reports on Form 8-K containing distribution or servicingreports filed in respect of periods included in the year covered by this annualreport, of Target Credit Card Master Trust;

 

2.  Based on my knowledge, theinformation in these reports, taken as a whole, does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading as of the last day of the period covered by thisannual report;

 

3.  Based on my knowledge, the distribution orservicing information required to be provided to the trustee by the servicerunder the pooling and servicing, or similar, agreement, for inclusion in thesereports is included in these reports;

 

4.  I am responsible for reviewing the activitiesperformed by the servicer under the pooling and servicing, or similar,agreement and based upon my knowledge and the annual compliance review requiredunder that agreement, and except as disclosed in the reports, the servicer hasfulfilled its obligations under that agreement; and

 

5.  The reports disclose all significantdeficiencies relating to the servicer’s compliance with the minimum servicingstandards based upon the report provided by an independent public accountant,after conducting a review in compliance with the Uniform Single AttestationProgram for Mortgage Bankers or similar procedure, as set forth in the poolingand servicing, or similar, agreement, that is included in these reports.

 

 
| Dated: May 6, 2005 | By     | /s/ Terrence J. Scully                                        |
|--------------------|--------|---------------------------------------------------------------|
|               |   |      Terrence  J. Scully,            |
|               |   |      Vice  President and Director    |
|               |   |      Target  Receivables Corporation |
771 P.2d 173

#### In the Matter of Dale B. DILTS, An Attorney Admitted to Practice Before the Courts of the State of New Mexico.

No. 18277.

Supreme Court of New Mexico.

March 22, 1989.

This matter coming on for consideration by the Court pursuant to SCRA 1986, 17-211(E), wherein the Chairperson of the Disciplinary Board has forwarded to the Court an Agreement Not to Contest and Consent to Sanctions signed by Dale B. Dilts and approved by disciplinary counsel. The Agreement has been reviewed by a Hearing Committee and a panel of the Disciplinary Board, and the Court hereby accepts the recommendation of the Board that the agreement be adopted.

In accordance with SCRA 1986, 17-209(B), Dale B. Dilts has submitted to a sworn statement admitting to violations of SCRA 1986, 16-101, 16-103 and 16-116 and agreeing to resign from the practice of law. Under the circumstances and in view of Dilts’ stated intention never to apply for reinstatement to the Bar of the State of New Mexico, the Court feels that the interests of the public will adequately be protected by this proposed disposition.

NOW, THEREFORE, IT IS ORDERED that the already tendered resignation of Dale B. Dilts is hereby accepted and that the effective date of said resignation be March 1, 1989;

IT IS FURTHER ORDERED that said resignation shall be permanent and that if, for any reason, Dilts should subsequently decide to apply for reinstatement to the Bar of the State of New Mexico, he may not do so except by leave of the Supreme Court and pursuant to procedures set forth in SCRA 1986, 17-209(E).

IT IS FURTHER ORDERED that the Clerk of this Court publish this Order in News and Views and in the New Mexico Reports.

Costs of this action in the amount of $102.30 are assessed against the said Dale B. Dilts and are to be paid to the Disciplinary Board on or before May 1, 1989.
U. S. Department of Homeland Security

 Office for Domestic Preparedness

 

Washington, D.C. 20531

ODP Information Bulletin

No. 80 September 22, 2003

TO: All State Administrative Agency Heads

All State Administrative Agency Points of Contact

FROM: Andrew T. Mitchell

Acting Director

SUBJECT: Relationship of the President’s Homeland Security Advisory Council Statewide

Template Initiative to the ODP State Homeland Security Assessment and Strategy

Process

On March 3, 2003, the President’s Homeland Security Advisory Council (HSAC) published the

Statewide Template Initiative. This document is intended to assist state, local and tribal

authorities with coordinated and comprehensive homeland security planning. It should be used

as a guide when completing the ODP State Homeland Security Assessment and Strategy

(SHSAS) process, and for other state and local planning efforts related to homeland security.

The questions asked in the Statewide Template Initiative document are designed to help you as

you complete the SHSAS process and submit your state’s Homeland Security Strategy to ODP

using the On-Line Data Collection Tool. However, please note that states are not required to

submit a second strategy to ODP or to the Department of Homeland Security (DHS) based on

or using the Statewide Template Initiative document.

For additional information on the SHSAS process, please contact the ODP Program Manager for

your state. ODP Program Managers may be reached through the ODP Helpline at:

1-800-368-6498.